Opaleye Management Inc. Buys Kiniksa Pharmaceuticals, Larimar Therapeutics Inc, CM Life Sciences Inc, Sells Autolus Therapeutics PLC, Gemini Therapeutics Inc, Checkpoint Therapeutics Inc

• New Purchases: LRMR, CMLF, FMTX, VIRX, PHVS, CDTX,
• Added Positions: KNSA, KROS, STRO, PTGX, OPTN, TELA, CMRX, HROW, PRQR, APTO, SRRA, LPTX, CRNX, LUMO,
• Reduced Positions: BBIO, XOMA, CERC, MGNX, ETON, MCRB, AVEO, CDXS, CRDF, NLTX, CFRX, DCPH, AFIB, KZR,
• Sold Out: AUTL, GMTX, CKPT, IMVT, CBIO, FGEN, MYOV, EDAP, CAPA, ALPN, BHVN, ARPO, AYLA, MGTA,

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

1. Ocular Therapeutix Inc (OCUL) - 6,480,000 shares, 15.26% of the total portfolio.
2. Chimerix Inc (CMRX) - 4,630,000 shares, 6.15% of the total portfolio. Shares added by 3.12%
3. Celldex Therapeutics Inc (CLDX) - 985,000 shares, 5.47% of the total portfolio.
4. BridgeBio Pharma Inc (BBIO) - 517,150 shares, 5.24% of the total portfolio. Shares reduced by 11.41%
5. Codexis Inc (CDXS) - 1,345,000 shares, 5.06% of the total portfolio. Shares reduced by 3.93%

Opaleye Management Inc. initiated holding in Larimar Therapeutics Inc. The purchase prices were between $8 and $15.2, with an estimated average price of $11.36. The stock is now traded at around $14.330000. The impact to a portfolio due to this purchase was 1.19%. The holding were 727,800 shares as of 2021-06-30.

Opaleye Management Inc. initiated holding in CM Life Sciences Inc. The purchase prices were between $10.75 and $16.75, with an estimated average price of $13.09. The stock is now traded at around $11.600000. The impact to a portfolio due to this purchase was 0.87%. The holding were 373,828 shares as of 2021-06-30.

Opaleye Management Inc. initiated holding in Forma Therapeutics Holdings Inc. The purchase prices were between $22.86 and $30.95, with an estimated average price of $26.91. The stock is now traded at around $23.000000. The impact to a portfolio due to this purchase was 0.71%. The holding were 171,000 shares as of 2021-06-30.

Opaleye Management Inc. initiated holding in Viracta Therapeutics Inc. The purchase prices were between $7.55 and $12.95, with an estimated average price of $10.02. The stock is now traded at around $9.700000. The impact to a portfolio due to this purchase was 0.48%. The holding were 257,189 shares as of 2021-06-30.

Opaleye Management Inc. initiated holding in Pharvaris NV. The purchase prices were between $18.05 and $29.59, with an estimated average price of $22.82. The stock is now traded at around $17.500000. The impact to a portfolio due to this purchase was 0.25%. The holding were 79,837 shares as of 2021-06-30.

Opaleye Management Inc. initiated holding in Cidara Therapeutics Inc. The purchase prices were between $1.87 and $2.7, with an estimated average price of $2.13. The stock is now traded at around $2.120000. The impact to a portfolio due to this purchase was 0.02%. The holding were 73,351 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in Kiniksa Pharmaceuticals Ltd by 259.96%. The purchase prices were between $13.22 and $19.09, with an estimated average price of $15.27. The stock is now traded at around $12.550000. The impact to a portfolio due to this purchase was 1.93%. The holding were 1,155,200 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in Keros Therapeutics Inc by 49.21%. The purchase prices were between $42.4 and $70.11, with an estimated average price of $54.36. The stock is now traded at around $33.420000. The impact to a portfolio due to this purchase was 0.55%. The holding were 235,000 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in Sutro Biopharma Inc by 45.31%. The purchase prices were between $18.03 and $23.82, with an estimated average price of $19.66. The stock is now traded at around $20.190000. The impact to a portfolio due to this purchase was 0.48%. The holding were 496,900 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in OptiNose Inc by 48.50%. The purchase prices were between $2.91 and $3.83, with an estimated average price of $3.41. The stock is now traded at around $2.570000. The impact to a portfolio due to this purchase was 0.21%. The holding were 1,226,600 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in TELA Bio Inc by 20.68%. The purchase prices were between $11.7 and $16.11, with an estimated average price of $13.74. The stock is now traded at around $14.100000. The impact to a portfolio due to this purchase was 0.2%. The holding were 440,465 shares as of 2021-06-30.

Opaleye Management Inc. added to a holding in Leap Therapeutics Inc by 39.14%. The purchase prices were between $1.48 and $1.92, with an estimated average price of $1.69. The stock is now traded at around $1.850000. The impact to a portfolio due to this purchase was 0.04%. The holding were 540,000 shares as of 2021-06-30.

Opaleye Management Inc. sold out a holding in Autolus Therapeutics PLC. The sale prices were between $4.78 and $7.96, with an estimated average price of $6.2.

Opaleye Management Inc. sold out a holding in Gemini Therapeutics Inc. The sale prices were between $6.32 and $14.02, with an estimated average price of $11.05.

Opaleye Management Inc. sold out a holding in Checkpoint Therapeutics Inc. The sale prices were between $2.36 and $3.2, with an estimated average price of $2.78.

Opaleye Management Inc. sold out a holding in Immunovant Inc. The sale prices were between $9.4 and $16.85, with an estimated average price of $14.06.

Opaleye Management Inc. sold out a holding in Catalyst Biosciences Inc. The sale prices were between $4.1 and $5.33, with an estimated average price of $4.59.

Opaleye Management Inc. sold out a holding in FibroGen Inc. The sale prices were between $18.57 and $35.68, with an estimated average price of $23.39.